The amount of upfront payment based on the agreement.

No definition available.

Name:	ptgx_CollaborativeAgreementUpfrontPayment
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount received from a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementEligibleAmountReceived
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the percentage of development cost incurred.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of development cost eliminated.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the development costs that have been eliminated.

+ References

No definition available.

+ Details

Name:	ptgx_DevelopmentCostsEliminated
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the duration of the parties' research collaboration agreement.

+ References

No definition available.

+ Details

Name:	ptgx_DurationOfResearchCollaborationAgreement
Namespace Prefix:	ptgx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentages on net product sales.

+ References

No definition available.

+ Details

Name:	ptgx_PercentagesRoyaltiesOnNetProductSales
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of reimbursement for services performed.

+ References

No definition available.

+ Details

Name:	ptgx_ReimbursementForServicesPerformed
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of development cost payable under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of development milestone payable under the research and collaboration agreement.

+ References

No definition available.

+ Details

Name:	ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents upcoming potential development milestones payment.

+ References

No definition available.

+ Details

Name:	ptgx_UpcomingPotentialDevelopmentMilestonesPayment
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_Ptg200PhaseAndSecondGenerationCompoundMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseTwoClinicalTrialSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseThreeClinicalTrialForAnyIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptgx_OriginalAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ptgx_UpfrontCashPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aEvaluatingPtg200Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_FinancialServiceOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreement - Narrative (Details) - USD ($)		3 Months Ended		12 Months Ended
	Jul. 27, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Mar. 31, 2020	May 07, 2019	Jul. 13, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Recognized revenue from deferred revenue contract liability		$ 13,000	$ 1,100,000
Janssen \| Services performed for IL-23 receptor antagonist compound research costs and other services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reimbursement for services performed		17,900,000
Janssen \| License and Collaboration Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue recorded following the contract modification		25,700,000	5,600,000
Janssen \| License and Collaboration Agreement \| Three phase 1 studies of second-generation compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible amount received				$ 7,500,000
Janssen \| License and Collaboration Agreement \| 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible amount received		25,000,000.0
Janssen \| License and Collaboration Agreement \| Phase 3 clinical trial for a second-generation compound for any indication
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upcoming potential development milestones		115,000,000.0
Janssen \| License and Collaboration Agreement \| Completion of clinical data collection for Phase 1 activities for the first of either PN-232 or PN-235
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upcoming potential development milestones		25,000,000.0
Janssen \| Original Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price				106,500,000
Janssen \| Original Agreement \| License and Collaboration Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Duration of the parties' research collaboration agreement	2 years
Janssen \| Original Agreement \| License and Collaboration Agreement \| Three phase 1 studies of second-generation compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expense obligations eliminated	$ 5,000,000.0
Percentage of development cost eliminated	50.00%
Janssen \| Original Agreement \| License and Collaboration Agreement \| Phase 2a and 2b costs for PTG-200
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost payable		$ 100,000,000.0
Development cost incurred, percentage		20.00%
Janssen \| Original Agreement \| License and Collaboration Agreement \| Phase 2 studies for second-generation products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of development cost eliminated	20.00%
Milestone payment							$ 50,000,000.0
Janssen \| Original Agreement \| License and Collaboration Agreement \| Maximum \| Three phase 1 studies of second-generation compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost payable							20,000,000.0
Janssen \| Original Agreement \| License and Collaboration Agreement \| Maximum \| Phase 2a and 2b costs for PTG-200
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost payable							20,000,000.0
Janssen \| Original Agreement \| License and Collaboration Agreement \| Maximum \| Phase 2 studies for second-generation products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost payable		$ 25,000,000.0
Expense obligations eliminated	$ 25,000,000.0
Janssen \| Original Agreement \| Upfront cash payment
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment							$ 50,000,000.0
Janssen \| Restated Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment		87,500,000
Development cost payable		7,100,000
Reimbursement for services performed		8,200,000
Maximum percentages royalties on net product sales	10.00%
Increase (decrease) in transaction price		25,000,000.0		$ 8,000,000.0
Transaction price		$ 131,500,000
Janssen \| Restated Agreement \| Second-generation Oral Interleukin ("IL")-23 Receptor Antagonist Development Compound
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible amount received					$ 5,000,000.0
Janssen \| Restated Agreement \| Phase 2a study evaluating PTG-200 for the treatment of CD
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost incurred, percentage		50.00%
Janssen \| Restated Agreement \| Additional services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		$ 0	$ 600,000
Janssen \| Restated Agreement \| License and Collaboration Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible amount received						$ 25,000,000.0
Janssen \| Restated Agreement \| License and Collaboration Agreement \| Phase 1 studies of second-generation compounds
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of development cost eliminated		100.00%
Janssen \| Restated Agreement \| License and Collaboration Agreement \| Phase 2 studies for second-generation products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upcoming potential development milestones		$ 25,000,000.0
Milestone payment	$ 25,000,000.0
Janssen \| Restated Agreement \| License and Collaboration Agreement \| 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upcoming potential development milestones		$ 10,000,000.0
Janssen \| Restated Agreement \| License and Collaboration Agreement \| Phase 2a study evaluating PTG-200 for the treatment of CD
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost incurred, percentage		20.00%
Janssen \| Restated Agreement \| License and Collaboration Agreement \| Dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upcoming potential development milestones		$ 50,000,000.0
Janssen \| Restated Agreement \| License and Collaboration Agreement \| Dosing Of Third Patient In Phase 3 Clinical Trial For Second Generation Compound For A Second Indication [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upcoming potential development milestones		15,000,000.0
Janssen \| Restated Agreement \| License and Collaboration Agreement \| Maximum \| Phase 2a study evaluating PTG-200 for the treatment of CD
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost payable		$ 20,000,000.0